发明名称 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF
摘要 Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
申请公布号 US2016376587(A1) 申请公布日期 2016.12.29
申请号 US201615007017 申请日期 2016.01.26
申请人 Sarepta Therapeutics, Inc. 发明人 Hanson Gunnar J.;Weller Dwight D.;Cai Bao Zhong;Zhou Ming
分类号 C12N15/113 主分类号 C12N15/113
代理机构 代理人
主权项 1. A compound having the structure of Formula (I):or a salt or isomer thereof, wherein: n is an integer from 2-35;G5 is halogen, OH, alkoxy, OSO2(alkyl), OSO2(aryl), or each B is an independently selected base pair moiety;each Y is independently O or NR10;each W is independently S or O;Z5 is -(L11)-(R15), -(L11)-(L15)-(R16), or -(L11)-(L12)-(R17);L11 is selected from:or k) —C(R23)2O—;wherein L13 is selected from: L12 is a linker cleaveable under biological conditions selected from: a) —(C1-C10 alkylene)-OC(O)O—CH2O—; b) —C(O)—(C1-C10 alkylene)-OC(O)O—CH2O—; c) —C(O)—(CH═CH)—C(O)O—CH2O—; d) —(C1-C10 alkylene)-S—S—CH2CH2O—; or e) —C(O)—(C1-C10 alkylene)-S—S—CH2CH2O—; L15 is divalent radical selected from C1-C30 alkylene, C3-C8 cycloalkylene, C6-C30 arylene, —(C6-C30 arylene)-(C1-C30 alkylene)-, —(C1-C30 alkylene)-C(═O)—, —(C2-C30 alkoxy)-C(═O)—, -(3-18 membered heteroalkylene)-C(═O)—, —(C3-C8 cycloalkylene)-C(═O)—, —(C3-C8 cycloalkylene)-(C1-C30 alkylene)-C(═O)—, —(C1-C30 alkylene) (C3-C8 cycloalkylene)-C(═O)—, —(C6-C30 arylene)-C(═O)—, —(C6-C30 arylene)-(C1-C30 alkylene)-C(═O)—, —(C1-C30 alkylene)-(C6-C30 arylene)-C(═O)—, —(C1-C30 alkylene)-O—C(═O)—, —(C3-C8 cycloalkylene)-O—C(═O)—, —(C7-C30 arylene)-O—C(═O)—, —(C6-C30 arylene)-(C1-C30 alkylene)-O—C(═O)—, —(C6-C30 arylene)-(C1-C30 alkylene)-O—C(═O)—, —C(═O)OR21, or —P(═O)(R22)2; R12 is an electron pair, with the provision that if R13 is C1-C30 alkyl, then R12 is an electron pair, an N-oxide, or C1-C6 alkyl; each R10 and R13 is independently selected from hydrogen, a cell-penetrating peptide, a natural or non-natural amino acid, guanidinyl, amidinyl, heterocyclyl, C1-C30 alkyl, C3-C8 cycloalkyl; C6-C30 aryl, C7-C30 aralkyl, C1-C30 alkylcarbonyl, C3-C8 cycloalkylcarbonyl, C3-C8 cycloalkylalkylcarbonyl, C6-C30 arylcarbonyl, C7-C30 aralkylcarbonyl, C1-C30 alkyloxycarbonyl, C3-C8 cycloalkyloxycarbonyl, C7-C30 aryloxycarbonyl, C8-C30 aralkyloxycarbonyl, —C(═O)OR21, —C(═O)NHR21, or —P(═O)(R22)2; R15 is independently selected from a cell-penetrating peptide, a natural or non-natural amino acid, guanidinyl, amidinyl, heterocyclyl, C1-C30 alkyl, C3-C8 cycloalkyl; C6-C30 aryl, C7-C30 aralkyl, C1-C30 alkylcarbonyl, C3-C8 cycloalkylcarbonyl, C3-C8 cycloalkylalkylcarbonyl, C6-C30 arylcarbonyl, C7-C30 aralkylcarbonyl, C2-C30 alkyloxycarbonyl, C3-C8 cycloalkyloxycarbonyl, C7-C30 aryloxycarbonyl, C8-C30 aralkyloxycarbonyl, 3-18 membered alkoxyalkylcarbonyl, —SO2R21, —C(═O)OR21, —P(═O)(OH)2 or —P(═O)(R22)2; R16 is a solid support matrix suitable for solid phase synthesis of oligonucleotides; R17 is a drug, protein or toxin; each R21 is independently C1-C30 alkyl, or a 3-18 membered alkoxyalkyl group; each R22 is independently an C6-C12 aryloxy; each R23 is independently H or C1-C6 alkyl; or optionally two R23 groups join to form a 3- to 8-membered ring; R24 is a C1-C6 alkylene; Q is independently selected from X1, X2, X3, X4, X5, X6, X7, or X8; each X is independently selected from X1, X2, X3, X4, X5, X6, X7, or X8 with wherein at least two instances of X are selected from X2, X3, X4, X5, X6, X7, or X8; wherein X1 is N(CH3)2; X2 is selected from: a) —O-alkylene-CO2H;b) —O-alkylene-CHN4;c) —N(R1)-alkylene-CO2H;d) —N(R1)-alkylene-CHN4;e) -L1-CO-alkylene-CO2H;f) -L1-CO-alkylene-CHN4;g) -L1-CO-alkenylene-CO2H;h) -L1-CO-alkenylene-CHN4;i) -L1-CO-arylene-CO2H;j) -L1-CO-arylene-CHN4;k) -L1-CONH-alkylene-CO2H;l) -L1-CONH-alkylene-CHN4;m) -L1-CONH-arylene-CO2H;n) -L1-CONH-arylene-CHN4;o) -L1-SO2-alkylene-CO2H;p) -L1-SO2-alkylene-CHN4;q) -L1-SO2-arylene-CO2H;r) -L1-SO2-arylene-CHN4;s) -L1-alkylene-CO2H;t) -L1-alkylene-CHN4;u) -L1-arylene-CO2H;v) -L1-arylene-CHN4; andw) a protected form of any of the above X2 groups; X3 is selected from: a) -L-alkyl;b) -L1-heterocyclyl;c) —O-alkylene-CNH—NH2;d) —N(R1)-alkylene-CNH—NH2;e) -L1-CNH—NH2;f) -L1-alkylene-CNH—NH2;g) -L1-arylene-CNH—NH2;h) -L1-CO-alkylene-CNH—NH2;i) -L1-CO-alkenylene-CNH—NH2;j) -L1-CO-arylene-CNH—NH2;k) -L1-CONH-alkylene-CNH—NH2;l) -L1-CONH-arylene-CNH—NH2;m) -L1-SO2-alkylene-CNH—NH2;n) -L1-SO2-arylene-CNH—NH2;o) —O-alkylene-N(R1)2;p) —N(R1)-alkylene-N(R1)2;q) -L1-N(R1)2;r) -L1-alkylene-N(R1)2;s) -L1-arylene-N(R1)2;t) -L1-CO-alkylene-N(R1)2;u) -L1-CO-alkenylene-N(R1)2;v) -L1-CO-arylene-N(R1)2;w) -L1-CONH-alkylene-N(R1)2;x) -L1-CONH-arylene-N(R1)2;y) -L1-SO2-alkylene-N(R1)2;z) —O-alkylene-N(R2)3;aa) —N(R1)-alkylene-N(R2)3;bb) -L1-N(R2)3;cc) -L1-alkylene-N(R2)3;dd) -L1-arylene-N(R2)3;ee) -L1-CO-alkylene-N(R2)3;ff) -L1-CO-alkenylene-N(R2)3;gg) -L1-CO-arylene-N(R2)3;hh) -L1-CONH-alkylene-N(R2)3;ii) -L1-CONH-arylene-N(R2)3;jj) -L1-SO2-alkylene-N(R2)3;kk) —O-alkylene-heterocyclyl;ll) —N(R1)-alkylene-heterocyclyl;mm) -L1-alkylene-heterocyclyl;nn) -L1-arylene-heterocyclyl;oo) -L1-CO-alkylene-heterocyclyl;pp) -L1-CO-alkenylene-heterocyclyl;qq) -L1-CO-arylene-heterocyclyl;rr) -L1-CONH-alkylene-heterocyclyl;ss) -L1-CONH-arylene-heterocyclyl;tt) -L1-SO2-alkylene-heterocyclyl;uu) —O-alkylene-N(O)(R2)2;vv) —N(R1)-alkylene-N(O)(R2)2;ww) -L-N(O)(R2)2;xx) -L-alkylene-N(O)(R2)2;yy) -L-arylene-N(O)(R2)2;zz) -L1-CO-alkylene-N(O)(R2)2;aaa) -L1-CO-alkenylene-N(O)(R2)23;bbb) -L1-CO-arylene-N(O)(R2)2;ccc) -L1-CONH-alkylene-N(O)(R2)2;ddd) -L1-CONH-arylene-N(O)(R2)2;eee) -L1-SO2-alkylene-N(O)(R2)2;fff) —O-alkylene-NH—CNH—NH2;ggg) —N(R1)-alkylene-NH—CNH—NH2;hhh) -L1-NH—CNH—NH2;iii) -L-alkylene-NH—CNH—NH2;jjj) -L-arylene-NH—CNH—NH2;kkk) -L1-CO-alkylene-NH—CNH—NH2;lll) -L1-CO-alkenylene-NH—CNH—NH2;mmm) -L1-CO-arylene-NH—CNH—NH2;nnn) -L1-CONH-alkylene-NH—CNH—NH2;ooo) -L1-CONH-arylene-NH—CNH—NH2;ppp) -L1-SO2-alkylene-NH—CNH—NH2;qqq) -L1-SO2-arylene-NH—CNH—NH2; andrrr) a protected form of any of the above X3 groups; X4 is selected from: a) —O-alkylene-aryl;b) —N(R1)-aryl;c) —N(R1)-alkylene-aryl;d) -L1-CO-alkylene-aryl;e) -L1-CO-alkenylene-aryl;f) -L1-CO-arylene-aryl;g) -L1-CONH-alkylene-aryl;h) -L1-CONH-arylene-aryl;i) -L1-SO2-alkylene-aryl;j) -L1-SO2-arylene-aryl;k) -L-alkylene-aryl;l) -L-arylene-aryl;m) —N(R1)-alkylene-N(R1)-aryl;n) —N(R1)-alkylene-N(R1)CO-aryl;o) —N(R1)-alkylene-N(R1)SO2-aryl;p) —N(R1)-alkylene-N(R1)CH2-aryl;q) -L-aryl;r) -L1-CO-aryl;s) -L1-SO2-aryl;t) -L1-alkylene-P(aryl)3;u) -L1-CO-alkylene-P(aryl)3;v) -L1-SO2-alkylene-P(aryl)3; andw) a protected form of any of the above X4 groups; X5 is selected from: a) —O-alkylene-heteroaryl;b) —N(R1)-alkylene-heteroaryl;c) -L1-CO-alkylene-heteroaryl;d) -L1-CO-alkenylene-heteroaryl;e) -L1-CO-arylene-heteroaryl;f) -L1-CONH-alkylene-heteroaryl;g) -L1-CONH-arylene-heteroaryl;h) -L1-SO2-alkylene-heteroaryl;i) -L1-S O2-arylene-heteroaryl;j) -L1-alkylene-heteroaryl;k) -L1-arylene-heteroaryl;l) —N(R1)-alkylene-N(R1)-hereroaryl;m) —N(R1)-alkylene-N(R1)CO-hereroaryl;n) —N(R1)-alkylene-N(R1)SO2-hereroaryl;o) —N(R1)-alkylene-N(R1)CH2-hereroaryl;p) -L-heteroaryl; andq) a protected form of any of the above X5 groups; X6 is selected from: a) —O-alkylene-(OCH2CH2)mOH;b) —O-alkylene-(OCH2CH2)mOCH3;c) —N(R1)-alkylene-(OCH2CH2)mOH;d) —N(R1)-alkylene-(OCH2CH2)mOCH3;e) —N(R1)-arylene-(OCH2CH2)mOH;f) —N(R1)-arylene-(OCH2CH2)mOCH3;g) -L-alkylene-(OCH2CH2)mOH;h) -L1-CO-alkylene-(OCH2CH2)mOH;i) -L1-CO-alkylene-(OCH2CH2)mOCH3;j) -L1-SO2-alkylene-(OCH2CH2)mOH;k) -L1-SO2-alkylene-(OCH2CH2)mOCH3;l) -L1-CO-arylene-(OCH2CH2)mOH;m) -L1-CO-arylene-(OCH2CH2)mOCH3;n) -L1-SO2-arylene-(OCH2CH2)mOH;o) -L1-SO2-arylene-(OCH2CH2)mOCH3;p) -L1-CO—(OCH2CH2)mOH;q) -L1-CO—(OCH2CH2)mOCH3;r) —N(R1)-(dibenzo-18-crown-6);s) an aza-crown ether; andt) a protected form of any of the above X6 groups; X7 is selected from: a) -heterocyclyl;b) —N(R1)(R3)c) -L1-hydrogen;d) -L-alkyl;e) -L1-CO-alkyl;f) -L1-CONH-alkyl;g) -L1-CON(alkyl)-alkyl;h) -L1-SO2-alkyl; andi) a protected form of any of the above X7 groups; X8 is selected from: a) -L1-CA;b) -L1-dCA;c) -L1-COCH2(R4)d) -L1-COCH(R4)NHCO2-alkyl;e) —OR5;f) a protected form of any of the above X8 groups;each R1 is independently hydrogen, alkyl, or a cell-penetrating peptide;each R2 is independently C1-C12 alkyl or optionally when two R2 are C1-C12 alkyl, two R2 are joined to form a heterocyclic ring;each R3 is independently C2-C18 alkyl, alkenyl, or alkynyl;each R4 is independently hydrogen, alkyl, hydroxyalkyl, sulfhydrylalkyl, or arylalkyl;each R5 is independently C1-C12 alkyl;each R6 is independently hydrogen or C1-C12 alkyl; L1 is selected from: wherein each Q1 and Q2 are each selected from a bond, —O— or —N(R6)—;each E1 is independently selected from optionally substituted aryl or optionally substituted heteroaryl;each E2 is independently an optionally substituted nitrogen containing heteroaryl;each L4 and L5 are each independently a bond, optionally substituted C1-C6 alkyl, or optionally substituted heteroalkyl; andm, p, q, s, and t are each independently 1-4.
地址 Corvallis OR US